Aligos Therapeutics, Inc. financial data

Symbol
ALGS on Nasdaq
Location
One Corporate Dr., 2 Nd Floor, South San Francisco, CA
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2025 - Nov 6, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 527 % +4.83%
Debt-to-equity 78.1 % +1.4%
Return On Equity -132 % -15.8%
Return On Assets -74.3 % -15.1%
Operating Margin -3.31K % -28.5%

Shares

Label TTM Value / Value Unit Change %
Common Stock, Shares, Outstanding 6.15M shares +85.1%
Entity Public Float 38.7M USD +91.6%
Common Stock, Value, Issued 9K USD +12.5%
Weighted Average Number of Shares Outstanding, Basic 10.4M shares +65.3%
Weighted Average Number of Shares Outstanding, Diluted 10.4M shares +65.3%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 2.62M USD -28.7%
Research and Development Expense 68.4M USD -10.5%
General and Administrative Expense 20.9M USD -13.1%
Operating Income (Loss) -86.7M USD +8.3%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -86.2M USD -12.4%
Income Tax Expense (Benefit) 311K USD +13.5%
Net Income (Loss) Attributable to Parent -86.5M USD -12.4%
Earnings Per Share, Basic -12 USD/shares +59.1%
Earnings Per Share, Diluted -19 USD/shares +35.6%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 41.9M USD +18.7%
Cash, Cash Equivalents, and Short-term Investments 99.1M USD +32.3%
Other Assets, Current 4.23M USD -11.7%
Assets, Current 103M USD +29.6%
Property, Plant and Equipment, Net 2.04M USD -21%
Operating Lease, Right-of-Use Asset 3.58M USD -33.6%
Other Assets, Noncurrent 713K USD +12.3%
Assets 110M USD +24.1%
Accounts Payable, Current 4.65M USD +69.7%
Employee-related Liabilities, Current 5.28M USD +19.8%
Accrued Liabilities, Current 13.6M USD -3.93%
Liabilities, Current 22M USD +4.92%
Operating Lease, Liability, Noncurrent 2.38M USD -57.1%
Liabilities 37.9M USD -1.04%
Accumulated Other Comprehensive Income (Loss), Net of Tax 455K USD -21.1%
Retained Earnings (Accumulated Deficit) -622M USD -16.1%
Stockholders' Equity Attributable to Parent 71.8M USD +43.4%
Liabilities and Equity 110M USD +24.1%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -20.9M USD +8.08%
Net Cash Provided by (Used in) Financing Activities 102M USD
Net Cash Provided by (Used in) Investing Activities -44.1M USD +50.3%
Common Stock, Shares Authorized 116M shares +457%
Common Stock, Shares, Issued 6.15M shares +85.1%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 42.1M USD +18.7%
Deferred Tax Assets, Valuation Allowance 56.5M USD +65.1%
Deferred Tax Assets, Gross 58.3M USD +59.2%
Operating Lease, Liability 8.22M USD -24.6%
Depreciation 839K USD -34.8%
Payments to Acquire Property, Plant, and Equipment 7K USD -98.6%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -86.6M USD -12.6%
Lessee, Operating Lease, Liability, to be Paid 9.05M USD -28.4%
Property, Plant and Equipment, Gross 14.5M USD +2.65%
Operating Lease, Liability, Current 3.54M USD +4.58%
Lessee, Operating Lease, Liability, to be Paid, Year Two 3.79M USD +3.04%
Lessee, Operating Lease, Liability, to be Paid, Year One 3.67M USD +3.06%
Operating Lease, Weighted Average Discount Rate, Percent 0.09 pure +12.6%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 835K USD -52.3%
Lessee, Operating Lease, Liability, to be Paid, Year Three 1.43M USD -62.3%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 771K USD +679%
Lessee, Operating Lease, Liability, to be Paid, Year Four 155K USD -89.3%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 1.76M USD -26.1%
Share-based Payment Arrangement, Expense 5.29M USD -43.3%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%